Peptide TherapeuticsPeer Reviewed

Combination Tripeptide/Hexapeptide Serum with 1540 nm Nonablative Fractional Laser for the Treatment of Striae Distensae: A Pilot Study.

Authors (4)
Kathleen P McGuinnDepartment of Dermatology and Cutaneous Biology, Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA.
Nicholas A RossDepartment of Dermatology and Cutaneous Biology, Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA.
Jordan V WangDepartment of Dermatology and Cutaneous Biology, Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA.
Nazanin SaediDepartment of Dermatology and Cutaneous Biology, Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA; nazanin.saedi@jefferson.edu.
Skinmed
Unknown
Published
Jan 01, 2020
View Original

Abstract

Striae distensae (SD) are associated with negative psychosocial effects. Improvements have been shown with non-ablative fractional lasers (NAFL). Topical peptides have also been effective in cutaneous rejuvenation; however, no studies have examined combination therapy for striae. Our study evaluated the efficacy and safety of a peri-procedural tripeptide/hexapeptide serum as an adjunct to 1540 nm NAFL for the treatment of SD in 10 patients. All patients reported subjective improvement. The addition of tripeptide/hexapep-tide serum increased the objective improvement, reduced the incidence of post-inflammatory hyperpigmentation, and increased patient satisfaction.

Keywords

AdultCombined Modality TherapyDermatologic AgentsFemaleHumansLow-Level Light TherapyMaleOligopeptidesPatient SatisfactionPilot ProjectsStriae DistensaeTreatment Outcome

Article Metrics

Sourcepubmed

Related Research

Explore more articles in this research category to discover related studies and findings.

View more in Peptide Therapeutics